Warning! GuruFocus detected
1 Severe warning sign
with MIRA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Mira Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US60458C1045
Description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2833 | |||||
| Equity-to-Asset | 0.75 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -52.6 | |||||
| 3-Year EPS without NRI Growth Rate | -51 | |||||
| 3-Year FCF Growth Rate | -57 | |||||
| 3-Year Book Growth Rate | -4.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.87 | |||||
| 9-Day RSI | 27.48 | |||||
| 14-Day RSI | 33.36 | |||||
| 3-1 Month Momentum % | -24.06 | |||||
| 6-1 Month Momentum % | -8.18 | |||||
| 12-1 Month Momentum % | -1.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.99 | |||||
| Quick Ratio | 3.99 | |||||
| Cash Ratio | 3.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -21.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -252.93 | |||||
| ROA % | -207.24 | |||||
| ROIC % | -12150 | |||||
| 3-Year ROIIC % | 834.42 | |||||
| ROC (Joel Greenblatt) % | -20047.5 | |||||
| ROCE % | -258.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.38 | |||||
| Price-to-Tangible-Book | 6.38 | |||||
| EV-to-EBIT | -1.27 | |||||
| EV-to-EBITDA | -1.27 | |||||
| EV-to-FCF | -1.88 | |||||
| Price-to-Net-Current-Asset-Value | 6.38 | |||||
| Price-to-Net-Cash | 6.38 | |||||
| Earnings Yield (Greenblatt) % | -78.74 | |||||
| FCF Yield % | -40.46 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers